Skip to main content
Premium Trial:

Request an Annual Quote

Lucigen, RCT Partner on Protein Expression System Lacking Endotoxin

NEW YORK (GenomeWeb News) – Lucigen and Research Corporation Technologies on Wednesday announced a commercialization and distribution partnership for the first Escherichia coli-based recombinant system without endotoxin.

The CleanColi Expression System is for protein expression and contains a genetically modified lipopolysaccharide that does not create an endotoxic response in human cells. Because of this, researchers will be able to increase their productivity since they will no longer need to remove unwanted endoxin, Lucigen and RCT said.

Lucigen will produce and sell kits containing CleanColi competent cells and provide contract research services for the CleanColi Expression System. The company also launched the CleanColi competent cell line.

RCT will manage the CleanColi commercial licensing programs.

Financial and other terms of the deal were not disclosed.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.